XFOR vs. ACB, TERN, FHTX, TSHA, CYRX, ANNX, CRVS, TRVI, CMPS, and AQST
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), Cryoport (CYRX), Annexon (ANNX), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), COMPASS Pathways (CMPS), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.
X4 Pharmaceuticals vs.
X4 Pharmaceuticals (NASDAQ:XFOR) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.
In the previous week, X4 Pharmaceuticals had 2 more articles in the media than Aurora Cannabis. MarketBeat recorded 3 mentions for X4 Pharmaceuticals and 1 mentions for Aurora Cannabis. X4 Pharmaceuticals' average media sentiment score of 0.73 beat Aurora Cannabis' score of 0.50 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.
72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 1.6% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aurora Cannabis has a net margin of 0.42% compared to X4 Pharmaceuticals' net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat X4 Pharmaceuticals' return on equity.
X4 Pharmaceuticals presently has a consensus target price of $3.50, suggesting a potential upside of 649.30%. Given X4 Pharmaceuticals' higher probable upside, equities research analysts plainly believe X4 Pharmaceuticals is more favorable than Aurora Cannabis.
Aurora Cannabis has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
X4 Pharmaceuticals has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.
Aurora Cannabis received 307 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. However, 67.54% of users gave X4 Pharmaceuticals an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote.
Summary
Aurora Cannabis beats X4 Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XFOR) was last updated on 2/22/2025 by MarketBeat.com Staff
